Drugs / RNK05047
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05487170 | Jul 2022 → Jun 2025 overdue | diffuse large B-cell lymphoma | Ranok Therapeutics (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-24 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Regulatory Ranok Therapeutics Announces U.S. FDA Clearance to Proceed with its First-in-Human Trial ranoktherapeutics.com ↗
Ranok Therapeutics, a biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for RNK05047, a novel treatment for patients with advanced solid tumors and lymphomas. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-13 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Ranok Therapeutics Expands Clinical Testing of CHAMP™ BRD4 Protein Degrader RNK05047 to China ranoktherapeutics.com ↗ |
| 2022-08-24 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047 ranoktherapeutics.com ↗ |
| 2022-01-24 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Ranok Therapeutics Announces U.S. FDA Clearance to Proceed with its First-in-Human Trial ranoktherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNK05047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487170 ↗ |
| Modality | Other / unclassified | “chaperone-mediated protein degrader” NCT05487170 ↗ |
| Route | Intravenous | “administered as IV infusion” NCT05487170 ↗ |